Skip to main content
SpringerLink
Log in

Standardized quality house dust mite sublingual tablets (Acarizax®): a guide to their use as sublingual allergy immunotherapy in Europe

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Standardized quality (SQ) house dust mite (HDM) allergen extract tablets (Acarizax®) are a valuable option for sublingual allergy immunotherapy (SLIT) in adults with confirmed HDM-induced allergic rhinitis or allergic asthma. In placebo-controlled natural-field and environmental exposure challenge chamber trials, Acarizax® reduced the symptoms of allergic rhinitis in adults with HDM-induced allergic rhinitis (± asthma) and reduced the risk of asthma exacerbations in adults with HDM-induced allergic asthma. A systemic antibody response to HDM allergens has been observed within 4 weeks of initiating SLIT with Acarizax®. Precautions should be followed to minimize the risk of systemic and local allergic reactions inherent to SLIT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Batard T, Baron-Bodo V, Martelet A, et al. Patterns of IgE sensitization in house dust mite-allergic patients: implications for allergen immunotherapy. Allergy. 2016;71(2):220–9.

    Article  CAS  PubMed  Google Scholar 

  2. Moingeon P. Progress in the development of specific immunotherapies for house dust mite allergies. Expert Rev Vaccines. 2014;13(12):1463–73.

    Article  CAS  PubMed  Google Scholar 

  3. Calderon MA, Linneberg A, Kleine-Tebbe J, et al. Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol. 2015;136(1):38–48.

    Article  PubMed  Google Scholar 

  4. Linneberg A, Henrik Nielsen N, Frølund L, et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy. 2002;57(11):1048–52.

    Article  CAS  PubMed  Google Scholar 

  5. Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008;372(9643):1049–57.

    Article  PubMed  Google Scholar 

  6. Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106(2 Suppl):S12–6.

    Article  PubMed  Google Scholar 

  7. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76.

    Article  PubMed  Google Scholar 

  8. Braido F, Arcadipane F, Marugo F, et al. Allergic rhinitis: current options and future perspectives. Curr Opin Allergy Clin Immunol. 2014;14(2):168–76.

    Article  CAS  PubMed  Google Scholar 

  9. Brehler R, Klimek L, Kopp MV, et al. Specific immunotherapy-indications and mode of action. Dtsch Arztebl Int. 2013;110(9):148–58.

    PubMed  PubMed Central  Google Scholar 

  10. Zuberbier T, Lotvall J, Simoens S, et al. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy. 2014;69(10):1275–9.

    Article  CAS  PubMed  Google Scholar 

  11. Calderon MA, Kleine-Tebbe J, Linneberg A, et al. House dust mite respiratory allergy: an overview of current therapeutic strategies. J Allergy Clin Immunol Pract. 2015;3(6):843–55.

    Article  PubMed  Google Scholar 

  12. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma and Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288–96.

    Article  PubMed  Google Scholar 

  13. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Biagtan M, Viswanathan R, Bush RK. Immunotherapy for house dust mite sensitivity: where are the knowledge gaps? Curr Allergy Asthma Rep. 2014;14(12):482.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Calderon MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67(3):302–11.

    Article  CAS  PubMed  Google Scholar 

  16. Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract. 2013;1(3):228–41.

    Article  PubMed  Google Scholar 

  17. Acarizax, lyophilized pellets: summary of product characteristics [in Danish]. Hørsholm: ALK-Abelló A/S; 2015.

  18. New medicine for house dust mite allergic rhinitis now available in Japan [media release]. 2015. http://www.benzinga.com/pressreleases/15/11/g6003590/new-medicine-for-house-dust-mite-allergic-rhinitis-now-available-in-jap. Accessed 15 Aug 2016.

  19. Henmar H, Frisenette SM, Grosch K, et al. Fractionation of source materials leads to a high reproducibility of the SQ house dust mite SLIT-tablets. Int Arch Allergy Immunol. 2016;169(1):23–32.

    Article  CAS  PubMed  Google Scholar 

  20. Fujita H, Soyka MB, Akdis M, et al. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy. 2012;2(1):2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Corzo JL, Carrillo T, Pedemonte C, et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. J Investig Allergol Clin Immunol. 2014;24(3):154–61.

    CAS  PubMed  Google Scholar 

  22. Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016;315(16):1715–24.

    Article  CAS  PubMed  Google Scholar 

  23. Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol. 2015;135(6):1494.e6–1501.e6.

    Article  Google Scholar 

  24. Mosbech H, Canonica GW, Backer V, et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann Allerg Asthma Immunol. 2015;114(2):134–40.

    Article  Google Scholar 

  25. Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014;134(3):568.e7–575.e7.

    Article  Google Scholar 

  26. Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2016;137(2):444–51.

    Article  CAS  PubMed  Google Scholar 

  27. Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016. doi:10.1016/j.jaci.2016.06.044.

    Google Scholar 

  28. Devillier P, Le Gall M, Horak F. The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy. Allergy. 2011;66(2):163–9.

    Article  CAS  PubMed  Google Scholar 

  29. Ellis AK, North ML, Walker T, et al. Environmental exposure unit: a sensitive, specific, and reproducible methodology for allergen challenge. Ann Allergy Asthma Immunol. 2013;111:323–8.

    Article  PubMed  Google Scholar 

  30. Ciprandi G, Cadario G, Di Gioacchino GM, et al. Sublingual immunotherapy in children with allergic polysensitization. Allergy Asthma Proc. 2010;31(3):227–31.

    Article  PubMed  Google Scholar 

  31. Radulovic S, Wilson D, Calderon M, et al. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011;66(6):740–52.

    Article  CAS  PubMed  Google Scholar 

  32. Maloney J, Prenner BM, Bernstein DI, et al. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. Ann Allergy Asthma Immunol. 2016;116(1):59–65.

    Article  PubMed  Google Scholar 

  33. Rønborg S, Johnsen CR, Theilgaard S, et al. Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark. J Med Econ. 2016;19(8):735–41.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The manuscript was reviewed by: S.A. Antoniu, Department of Preventive Medicine and Interdisciplinarity, ‘Grigore T. Popa’ University of Medicine and Pharmacy, Iaşi, Romania; F. Guarneri, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; C. Page, Sackler Institute of Pulmonary Pharmacology, King’s College London, London, UK; C. Sitaru, Department of Dermatology and Venereology, University of Freiburg, Freiburg, Germany; Y. Yeniay, Department of Dermatology, Gölcük Military Hospital, Gölcük, Turkey. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

K. A. Lyseng-Williamson is a salaried employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Standardized quality house dust mite sublingual tablets (Acarizax®): a guide to their use as sublingual allergy immunotherapy in Europe. Drugs Ther Perspect 32, 502–509 (2016). https://doi.org/10.1007/s40267-016-0349-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-016-0349-7

Keywords

Search

Navigation